Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment

Long-acting parenteral formulations of antiretrovirals could facilitate maintenance and prophylactic treatment in HIV. Using the poorly water- and oil-soluble non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine) as base or hydrochloride (HCl), nanosuspensions were prepared by...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of pharmaceutics and biopharmaceutics 2009-08, Vol.72 (3), p.502-508
Hauptverfasser:	Baert, Lieven, van ‘t Klooster, Gerben, Dries, Willy, François, Marc, Wouters, Alfons, Basstanie, Esther, Iterbeke, Koen, Stappers, Fred, Stevens, Paul, Schueller, Laurent, Van Remoortere, Pieter, Kraus, Guenter, Wigerinck, Piet, Rosier, Jan
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Biological and medical sciences Chemistry, Pharmaceutical Delayed-Action Preparations - administration & dosage Delayed-Action Preparations - chemical synthesis Delayed-Action Preparations - pharmacokinetics Dogs Female General pharmacology HIV HIV Infections - drug therapy HIV Infections - virology HIV Reverse Transcriptase - antagonists & inhibitors HIV-1 - drug effects HIV-1 - enzymology HIV-1 - growth & development Injectable Injections, Intramuscular Injections, Subcutaneous Long-acting Male Medical sciences Mice Nanoparticles - administration & dosage Nanoparticles - chemistry Nitriles - administration & dosage Nitriles - chemical synthesis Nitriles - pharmacokinetics Pharmaceutical technology. Pharmaceutical industry Pharmacokinetics Pharmacology. Drug treatments Pyrimidines - administration & dosage Pyrimidines - chemical synthesis Pyrimidines - pharmacokinetics Rilpivirine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!